MY182434A - Certain chemical entities, compositions, and methods - Google Patents

Certain chemical entities, compositions, and methods

Info

Publication number
MY182434A
MY182434A MYPI2016000328A MYPI2016000328A MY182434A MY 182434 A MY182434 A MY 182434A MY PI2016000328 A MYPI2016000328 A MY PI2016000328A MY PI2016000328 A MYPI2016000328 A MY PI2016000328A MY 182434 A MY182434 A MY 182434A
Authority
MY
Malaysia
Prior art keywords
methods
compositions
chemical entities
certain chemical
entities
Prior art date
Application number
MYPI2016000328A
Inventor
Xiangping Qian
Yong-Liang Zhu
Original Assignee
Neupharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neupharma Inc filed Critical Neupharma Inc
Priority claimed from PCT/US2014/052409 external-priority patent/WO2015027222A2/en
Publication of MY182434A publication Critical patent/MY182434A/en

Links

Abstract

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
MYPI2016000328A 2013-08-23 2014-08-22 Certain chemical entities, compositions, and methods MY182434A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361869896P 2013-08-23 2013-08-23
US201361900283P 2013-11-05 2013-11-05
US201462000946P 2014-05-20 2014-05-20
PCT/US2014/052409 WO2015027222A2 (en) 2013-08-23 2014-08-22 Certain chemical entities, compositions, and methods

Publications (1)

Publication Number Publication Date
MY182434A true MY182434A (en) 2021-01-25

Family

ID=87570767

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016000328A MY182434A (en) 2013-08-23 2014-08-22 Certain chemical entities, compositions, and methods

Country Status (1)

Country Link
MY (1) MY182434A (en)

Similar Documents

Publication Publication Date Title
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
CL2015001985A1 (en) Thiazolcarboxamides and pyridinecarboxamide compounds, pim kinase inhibitors.
MX2018008052A (en) Lsd1 inhibitors.
MX2019001125A (en) Macrocycle kinase inhibitors.
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
MX371108B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors.
MX2016003843A (en) Irak inhibitors and uses thereof.
CL2015002932A1 (en) Protein kinase inhibitors
MY187540A (en) Compounds active towards bromodomains
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX2015008999A (en) Mk2 inhibitors and uses thereof.
IL253979A0 (en) Methods, compositions, and kits for treatment of cancer
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX2015011899A (en) Methods of treating cancer and preventing cancer drug resistance.
MX2015011606A (en) Methods of treating cancer and preventing cancer drug resistance.
MX2015006478A (en) Glutamase inhibitors and method of use.
MX2020001756A (en) Benzoquinolone inhibitors of vmat2.
MX2016004570A (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy.
TN2015000411A1 (en) Ceftolozane antibiotic compositions
EP2670763A1 (en) Certain chemical entities, compositions, and methods
MX2016009655A (en) Novel methods for treating cancer.
PH12016501838A1 (en) Compounds and their methods of use
MX2015013021A (en) 5-bromo-indirubins.